Health National News

DCGI approved the emergency use of Kovishield and Kovaxin

India is moving towards a two-way victory in the battle with Corona. Amid the shortage of new cases of infection every day, now the dual weapon of the vaccine has also come into the hands of the country. The drug regulator Drug Controller General of India (DCGI) on Sunday approved the emergency use of Kovishield of Serum Institute and Kovaxin of Bharat Biotech, ratifying the recommendation of the Subject Expert Committee (SEC). DCGI Dr. VG Somani has described both vaccines as effective and completely safe against the coronavirus.

A senior health ministry official said that if everything goes well, vaccination can start by 6 or 7 January. Under this, three crore health workers, security personnel and sanitation workers will be given a dose of corona vaccine on a priority basis.

Immediately after the approval of DCGI, the process of purchase of the vaccine was done with the Ministry of Health, Serum Institute and Bharat Biotech started finalizing. The availability of the dose of the vaccine as well as its price is being negotiated in this regard.

The Health Ministry is trying to know from both companies that in the next two-three or six months they will be able to provide the dose of vaccine and at what cost. The serum institute’s Kovishield is expected to be priced between Rs 200 and Rs 250. Right there, the price of Biotech Covaxin is not yet clear. It has not yet been told how many doses of the vaccine have been prepared so far.

Related posts

PM launches construction works of Ahmedabad and Surat Metro Project


Transfer policy of teachers will change in Haryana


India Government Approves Navy’s Proposal to purchase Shipborne Drones


Supreme Court approves Central Vista project

Sam Vinayak

Air Force to get 83 Tejas Aircraft, Government approves 48 thousand crore deal


Railways hope to run all trains by March